Results 211 to 220 of about 3,679,356 (272)
Some of the next articles are maybe not open access.
Hypomethylating Agents in Lymphoma
Current Treatment Options in Oncology, 2020Epigenetic mutations are frequent and pathogenic in select subtypes of lymphoma, and agents modulating DNA and histone methylation-such as inhibitors of DNMT and EZH2, respectively-have demonstrated promise in treating these diseases. In particular, lymphomas derived from the germinal center-GC-DLBCL, FL, and AITL-are all characterized by epigenetic ...
Jacob C, Cogan +2 more
openaire +2 more sources
Leukemia and Lymphoma, 2023
We retrospectively analyzed the outcomes of 136 consecutive patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center.
Li Li +9 more
semanticscholar +1 more source
We retrospectively analyzed the outcomes of 136 consecutive patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center.
Li Li +9 more
semanticscholar +1 more source
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
Current Hematologic Malignancy Reports, 2023To discuss novel targeted therapies under investigation for treatment of myelodysplastic neoplasms (MDS).Over the last few years, results of phase 3 trials assessing novel therapies for high-risk MDS have been largely disappointing. Pevonedistat (NEDD-8 inhibitor) and APR-246 (TP53 reactivator) both did not meet trial endpoints.
Prateek Pophali +2 more
openaire +2 more sources
Drug resistance updates, 2022
Resistance to the hypomethylating agents (HMAs) 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) represents a major obstacle in the treatment of elderly patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) which are not ...
K. Simonicova +5 more
semanticscholar +1 more source
Resistance to the hypomethylating agents (HMAs) 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) represents a major obstacle in the treatment of elderly patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) which are not ...
K. Simonicova +5 more
semanticscholar +1 more source
Hypomethylating Agents for Urologic Cancers
Future Oncology, 2011Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm ...
Ajjai S, Alva +5 more
openaire +2 more sources
American journal of hematology/oncology, 2022
Azacitidine and decitabine are hypomethylating agents that have dose‐dependent epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
N. Short, H. Kantarjian
semanticscholar +1 more source
Azacitidine and decitabine are hypomethylating agents that have dose‐dependent epigenetic and cytotoxic effects and are widely used in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
N. Short, H. Kantarjian
semanticscholar +1 more source
Hypomethylating agents and chemotherapy in MDS
Best Practice & Research Clinical Haematology, 2013Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline-AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype ...
Adès, Lionel, SANTINI, VALERIA
openaire +3 more sources
Optimizing hypomethylating agents in myelodysplastic syndromes
Current Opinion in Hematology, 2012Hypomethylating agents (HMAs) improve the outcome of higher-risk myelodysplastic syndromes (MDS) and provide multilineage response in lower-risk patients but their results must be optimized, especially as the poor outcome of patients after HMA failure is now established.Current efforts include evaluation of novel outpatient administration schedules and
Raphael, Itzykson, Pierre, Fenaux
openaire +2 more sources
Journal of Internal Medicine, 2022
The heterogeneity of relapsed or refractory (R/R) acute myeloid leukemia (AML) leads to no response to venetoclax (VEN)–based therapy in more than half of the patients. Genetic characteristics are considered important predictors for response to treatment
Guangyang Weng +16 more
semanticscholar +1 more source
The heterogeneity of relapsed or refractory (R/R) acute myeloid leukemia (AML) leads to no response to venetoclax (VEN)–based therapy in more than half of the patients. Genetic characteristics are considered important predictors for response to treatment
Guangyang Weng +16 more
semanticscholar +1 more source
Curcumin is a potent DNA hypomethylation agent
Bioorganic & Medicinal Chemistry Letters, 2009Molecular docking of the interaction of curcumin and DNMT1 suggested that curcumin covalently blocks the catalytic thiolate of C1226 of DNMT1 to exert its inhibitory effect. This was validated by showing that curcumin inhibits the activity of M. SssI with an IC(50) of 30 nM, but no inhibitory activity of hexahydrocurcumin up to 100 microM. In addition,
Zhongfa, Liu +11 more
openaire +2 more sources